Delving into the Latest Updates on Besins Healthcare (UK) Ltd. with Synapse

概览

疾病领域	数量

内分泌与代谢疾病	1

排名前五的药物类型	数量

小分子化药	1

排名前五的靶点	数量

AR(雄激素受体)	1

关联

1

项与 Besins Healthcare (UK) Ltd. 相关的药物

Testosterone

睾酮

靶点

AR

作用机制

AR激动剂

在研机构

原研机构

在研适应症

非在研适应症

最高研发阶段批准上市

首次获批国家/地区

美国

首次获批日期1995-09-29

100 项与 Besins Healthcare (UK) Ltd. 相关的临床结果

登录后查看更多信息

0 项与 Besins Healthcare (UK) Ltd. 相关的专利（医药）

登录后查看更多信息

2

项与 Besins Healthcare (UK) Ltd. 相关的文献（医药）

2018-06-01·Reproductive BioMedicine Online3区 · 医学

Systematic review of the clinical efficacy of vaginal progesterone for luteal phase support in assisted reproductive technology cycles

3区 · 医学

Review

作者: Evans, Jennifer S ; Child, Tim ; Lass, Amir ; Leonard, Saoirse A

Vaginal progesterone via capsule, gel or tablet is the most common route for luteal phase support (LPS) in Europe. Although there is a wealth of data comparing products used at other stages of assisted reproductive technology cycles, there is a lack of systematically identified evidence comparing the wide range of vaginal progesterone products. This systematic review queried the MEDLINE, Embase and Cochrane Library databases on 30 June 2016 to identify head-to-head randomized controlled trials (RCTs) comparing the efficacy or safety of vaginal progesterone preparations (Crinone, Cyclogest, Lutigest or Utrogestan Vaginal) for LPS in assisted reproductive technology cycles. Of 1914 results, 18 RCTs were included. No significant difference in clinical pregnancy rate was identified in comparisons of Utrogestan Vaginal with Crinone. Utrogestan Vaginal and Lutigest were non-inferior to Crinone in ongoing pregnancy rate comparisons. Differences in patient-reported perineal irritation with Crinone and Lutigest were not significantly different to Cyclogest. In studies comparing varying timing or dosage of Utrogestan Vaginal or Crinone, no significant differences were observed. These results suggest Crinone, Cyclogest, Lutigest and Utrogestan Vaginal represent equally safe and effective choices of vaginal progesterone for LPS in assisted reproductive technology cycles. Future quantitative analyses could provide further support for these findings.

2018-03-01·Experimental and Clinical Endocrinology & Diabetes4区 · 医学

Screening for Hypogonadism in Primary Healthcare: How to do this Effectively

4区 · 医学

Article

作者: Jones, Richard ; Moreno, Gabriela ; Donnahey, Gemma ; Hackett, Geoff ; Heald, Adrian ; Livingston, Mark ; Duff, Christopher

Abstract Background Testosterone, the most important androgen produced by the testes, plays an integral role in male health. Testosterone levels are increasingly being checked in primary healthcare as awareness of the risks of male hypogonadism grows. Aim To investigate what tests are performed to screen for hypogonadism and to exclude secondary hypogonadism. Design and Setting All participants attended general practices in the UK. Methods Data search was performed using the EMIS® clinical database (provider of the majority of GP operating systems in Cheshire). The anonymised records of male patients aged 18–98 years who had undergone a check of serum testosterone during a 10-year period were analysed. Results Overall screening rate was 4.3%. Of 8 788 men with a testosterone result, 1 924 men (21.9%) had a total testosterone level <10 nmol/L. Just 689 of 8 788 men (7.8%) had a sex hormone-binding globulin (SHBG) result, corresponding to 30.5% of those potentially hypogonadal. Estimated free testosterone was negatively associated with BMI (Spearman’s rho -0.2, p<0.001) as was total testosterone in the over 50 s. Of 1 924 potentially hypogonadal men with a serum testosterone <10 nmol/L, 588 of 1 924 (30.6%) had a check of serum prolactin. 46.3% and 41.7% had LH and FSH measured, respectively. Only 19.1% of 1 924 men with a hypogonadal total testosterone level were subsequently put on testosterone replacement. The percentage of men in the relatively socially disadvantaged category was similar for both eugonadal and hypogonadal men with a much higher rate of screening for hypogonadism in more socially advantaged men. Conclusions Screening in primary healthcare identified a significant minority of men who had potential hypogonadism. Interpretation of a low serum testosterone requires measurement of serum prolactin, LH and FSH in order to rule out secondary hypogonadism. We suggest that this becomes part of routine screening with a balanced screening approach across the socioeconomic spectrum.

100 项与 Besins Healthcare (UK) Ltd. 相关的药物交易

登录后查看更多信息

100 项与 Besins Healthcare (UK) Ltd. 相关的转化医学

登录后查看更多信息